Results for tag: "Glucagon Like Peptide 2 Receptor"

The Glucagon Like Peptide 2 Receptor (GLP-2R) is a G-protein coupled receptor that is involved in the regulation of glucose homeostasis and energy balance. It is a target for the development of drugs for the treatment of metabolic diseases such as diabetes and obesity. GLP-2R agonists are also being investigated for their potential to treat diseases of the central nervous system, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. GLP-2R agonists are being developed by a number of pharmaceutical companies, including Novo Nordisk, Eli Lilly, Merck, and AstraZeneca. These companies are researching the potential of GLP-2R agonists to treat a variety of diseases, including metabolic and neurological disorders. Additionally, several biotechnology companies are developing GLP-2R agonists for the treatment of metabolic diseases. Show Less Read more